Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Mireia Gil RagaIrene Paredero PérezRebeca Chulvi VeigaMarcos Melian SosaMaria José Safont AguileraPaula Llor RodríguezMaría Teresa Taberner BonastreJorge Aparicio UrtasunLaura Palomar AbadIsabel Busquier HernándezPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2023)
Our results confirm the value of maintaining angiogenesis inhibition with FOLFIRI-aflibercept in mCRC after progression to a first-line treatment with bevacizumab. The development of hypertension during treatment is a possible predictive marker of response.